Masimo Expands Board of Directors

Masimo Corporation, a developer of noninvasive patient monitoring technologies, has appointed medical device executive Craig B. Reynolds to its Board of Directors. Reynolds also will serve as a member of the board’s Audit and Compensation committees.

“Masimo has been at the forefront of medical technology innovation, patient safety, and cost efficiencies in hospital environments—and has done so with ethics and integrity,” Reynolds said. “I look forward to joining the Board of Directors and I am confident that my medical device experience will allow me to contribute to Masimo’s continued success.”

Reynolds, 65, has served as a director of Symmetry Medical Inc. since Jan. 4, 2008, and currently is board chairman. He is the CEO and a director of Cereve Inc., a company engaged in resolving insomnia. Prior to joining Cereve, Reynolds served as Chief Operating Officer (COO) of Philips Respironics Home Health Solutions, a subsidiary of Philips, from 2008 to 2010. Prior to Philips Respironics, Reynolds was the COO and a board member of Respironics Inc. , a company that develops, manufactures and markets sleep and respiratory devices. Reynolds also served as CEO and director of Healthdyne Technologies Inc.

Reynolds earned his B.S. in industrial management from the Georgia Institute of Technology and his M.B.A. from Georgia State University.

“We are honored to have a professional of Craig’s caliber on our team,” said Masimo Chairman and CEO Joe Kiani. “Craig brings a unique combination of Executive and Board experience from the medical technology sector as well as a long track record of doing the right things the right way. As a result, I am confident that he will be a valuable member of our board.”

Based in Irvine, Calif., Masimo develops noninvasive patient monitoring technologies. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET, which virtually eliminated false alarms and increased pulse oximetry’s ability to detect life-threatening events, according to the company. More than 100 independent and objective studies have shown that Masimo SET outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin, oxygen content, carboxyhemoglobin, methemoglobin, and PVI, in addition to SpO2, pulse rate, and perfusion index.